Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results

Loading news article.

Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results | WAPE

Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results

Article summary

Related companies

Comments —